Sage Healthcare and Roth Capital Partners have announced a strategic collaboration to identify and assess ex-US healthcare and life-science companies that may benefit from Sage's transaction advisory experience and Roth's US capital markets expertise.

​

The collaboration may be relevant to companies approaching clinical, regulatory or commercial milestones, seeking public or private equity financing, or considering licensing, partnering, M&A and financing alternatives in parallel.

​

The collaboration brings together Sage's specialist capabilities in licensing, partnering and M&A, its European healthcare network and Roth's healthcare investment banking, financing strategy and US capital markets services.

​

It is designed for selected companies where strategic transaction planning and financing needs are closely connected - for example, businesses approaching clinical, regulatory or commercial milestones, evaluating partnering or M&A alternatives, or seeking equity capital to support development and growth.

​

Sage can support transaction readiness, strategic positioning, partner and buyer identification, market engagement and execution. Roth may, subject to its independent assessment, approvals, regulatory requirements and a separate engagement where appropriate, evaluate relevant companies for financing, institutional investor access and other investment-banking or capital-markets services.

​

If your company is considering licensing, partnering, M&A, public or private equity financing - or wishes to assess several alternatives in parallel - we would welcome an initial confidential discussion.

​

To discuss whether this may be relevant to your company, please contact Dr Bill Mason at wtm@sagehealthcare.com.​

​

​

​​